()

()  — particularly in low- and middle-income countries (LMICs).

In many low-resource settings, due to the high cost of systems, their complexity, and the infrastructure and training they require. Without timely access to results, clinicians are often forced to treat infections empirically, which can lead to ().

At Zynnon , we are working to change this.

We’ve developed a -, - designed to bring blood culture-based testing closer to patients. By sampling () , our device can detect microbial growth across , , — making accurate diagnosis more accessible and scalable.

Our mission: enable , , where they are needed most, to improve patient outcomes and help combat AMR worldwide.

✨ : we’ll be showcasing our solution at the very soon. Stay tuned!

Exhibitor Data Sheet